State Street Corp Arcus Biosciences, Inc. Put Options Transaction History
State Street Corp
- $2.21 Trillion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding RCUS
# of Institutions
186Shares Held
49.2MCall Options Held
204KPut Options Held
149K-
Black Rock Inc. New York, NY9.9MShares$140 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.79MShares$67.7 Million0.0% of portfolio
-
Woodline Partners LP San Francisco, CA2.88MShares$40.7 Million0.52% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct1.91MShares$27 Million0.09% of portfolio
-
Dimensional Fund Advisors LP Austin, TX1.62MShares$22.9 Million0.01% of portfolio
About Arcus Biosciences, Inc.
- Ticker RCUS
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 72,160,000
- Market Cap $1.02B
- Description
- Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...